Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

20.18EUR
8 Dec 2017
Change (% chg)

€0.57 (+2.91%)
Prev Close
€19.61
Open
€19.74
Day's High
€20.50
Day's Low
€19.72
Volume
408,513
Avg. Vol
372,349
52-wk High
€20.50
52-wk Low
€9.75

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.58
Market Cap(Mil.): €1,507.86
Shares Outstanding(Mil.): 74.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Ablynx 9-month revenues decrease to 44.7 million euros ​

* 9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​

Nov 16 2017

BRIEF-Ablynx announces full exercise of underwriters' option to purchase additional shares

* ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

Oct 27 2017

BRIEF-Ablynx prices $200 mln IPO in the United States

* Ablynx prices $200 million initial public offering in the United States

Oct 24 2017

BRIEF-Ablynx NV now sees IPO of up to 9.5 mln ordinary shares

* Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing

Oct 24 2017

BRIEF-Ablynx NV offers 9.2 million of its ordinary shares in global offering

* Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing

Oct 20 2017

BRIEF-Ablynx to offer and sell about $175 million of its ordinary shares

* ‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​

Oct 17 2017

BRIEF-Ablynx establishes subsidiary in USA

* ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 16 2017

BRIEF-Ablynx NV files for U.S. IPO of up to $150 mln

* Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​

Oct 02 2017

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

Oct 02 2017

Belgian biotech Ablynx scores big hit with blood disease drug

Oct 2 Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

Oct 02 2017

Earnings vs. Estimates